Lyell Immunopharma, Inc.LYELNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank67
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-150.02M
↓ 18% vs avg
Percentile
P67
Within normal range
Streak
3 yr
Consecutive growthContracting
Average
$-127.62M
Historical baseline
PeriodValueYoY Change
2025$-150.02M+7.6%
2024$-162.39M+0.8%
2023$-163.69M+3.5%
2022$-169.56M-34.3%
2021$-126.25M+21.5%
2020$-160.87M-507.5%
2019$39.47M-